Hsp40-Targeting Compounds Overcome AR Resistance in Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for advanced prostate cancer, particularly castrate-resistant prostate cancer, face challenges due to the development of resistance to antiandrogen therapy, primarily driven by increased androgen receptor (AR) expression, where existing antiandrogens demonstrate partial agonist properties and fail to inhibit AR-dependent pathways effectively.
Innovation Solution
Development of compounds that target Hsp40 and indirectly regulate the androgen receptor pathway, inhibiting AR expression and AR-dependent gene expression without binding to the androgen receptor, thereby overcoming resistance to traditional antiandrogens like MDV3100.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first generation AR antagonists (bicalutamide, flutamide) are used to treat prostate cancer, then they can block androgen receptor signaling, but they demonstrate agonist properties in cells with increased AR expression and fail to retain antagonism in cells expressing excess AR
Solution Approach 1:
The patent employs parameter changes by developing second generation antiandrogens with modified chemical structures (Formula I compounds) that alter the binding characteristics and pharmacological properties to maintain antagonism in high AR expression environments
Solution Approach 2:
The patent uses heat shock protein 40 (Hsp40) as an intermediary target. The compounds bind to Hsp40 rather than directly to the androgen receptor, indirectly regulating the AR pathway and overcoming resistance mechanisms that develop with direct AR antagonists
2Reliability
If compounds are designed to directly bind androgen receptor to inhibit AR signaling, then they can block AR activation, but they lose effectiveness when AR expression increases or AR mutations occur
Solution Approach 1:
The patent uses heat shock protein 40 (Hsp40) as an intermediary target. The compounds bind to Hsp40 rather than directly to the androgen receptor, indirectly regulating the AR pathway and overcoming resistance mechanisms that develop with direct AR antagonists
Solution Approach 2:
The patent achieves universality by creating compounds that can effectively treat multiple forms of prostate cancer including those with wild-type AR, mutated AR, and increased AR expression, through a single mechanism of Hsp40 binding
Data Source
AI summary
Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I:wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.